Archive for the ‘Gene Therapy Research’ Category

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics,Inc. (ILIU) today announced financial and operational results for the third quarter ended September 30, 2012.

Total revenue for the three months ended September 30, 2012 was $420,000, compared to $765,000 for the same period in the prior year. The decrease was primarily attributable to a decrease in genetic tests returned and processed and lower sales of our Inherent Health brand of genetic tests through our Merchant Network and Channel Partner Agreement with Amway Global. Cash received from genetic test sales is reflected as deferred revenue until the test report is issued. Deferred revenue increased $146,000 to $971,000 at September 30, 2012 as compared to December 31, 2011.

Research and development expenses were $246,000 for the three months ended September 30, 2012, compared to $325,000 for the same period in the prior year. The decrease was primarily attributable to lower consulting costs partially offset by increased compensation costs.

Selling, general, and administrative expenses were $1.0 million for the three months ended September 30, 2012, compared to $1.1 million for the same period in the prior year. The decrease was primarily attributable to lower patent related legal fees, insurance, consulting and sales commissions paid to Amway partially offset by increased professional fees and employee separation costs.

The Company reported a net loss of $1.3 million, or $(.03) per basic and diluted common share, for the third quarter of 2012 compared to $1.1 million, or $(.03) per basic and diluted common share, for the same period in 2011. On September 30, 2012, the Company had cash and cash equivalents of $2.5 million.

The Company expects that its current and anticipated financial resources are adequate to maintain current and planned operations at least through November 30, 2012, the due date of its credit facility with Pyxis Innovations, Inc., and through March 31, 2013 if the due date of the credit facility is extended. Management is in discussions with Pyxis to extend this due date. The Companys independent registered public accounting firm has included an explanatory paragraph in their opinion in connection with the 2011 audit, relating to the Company's ability to continue as a going concern.

We are encouraged by the positive top line results received from the University of Michigan study that employed our PST test. The results of the study should provide the evidence to support broader use of this test to both improve preventive dental care and favorably influence healthcare costs. We are now focused on ramping up the broad commercialization of our PST genetic test for improved management of dental patients, said Kenneth S. Kornman, Chief Executive Officer of Interleukin Genetics.

Conference Call and Webcast Information

Interleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EST to review the Companys new business developments and third quarter financial results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast and replay access will be available on the Investors section of the Companys Website at: http://www.ilgenetics.com.

Read the original here:
Interleukin Genetics Reports Third Quarter 2012 Financial Results

SALT LAKE CITY, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Piper Jaffray Healthcare Conference, at 4:00 p.m. Eastern Time on Tuesday, November 27, 2012. The conference is being held at The New York Palace in New York, New York.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Read more:
Myriad Genetics to Present at the Piper Jaffray Healthcare Conference

Essentials Of Genomic And Personalized Medicine
ll4.me Essentials Of Genomic And Personalized Medicine Derived from the comprehensive two-volume set, Genomic and Personalized Medicine also edited by Drs. Willard and Ginsburg, this work serves the needs of the evolving population of scientists, researchers, practitioners and students that are embracing one of the most promising avenues for advances in diagnosis, prevention and treatment of human disease. From principles, methodology and translational approaches to genome discoveries and clinical applications, Essentials ofGenomic and Personalized Medicine will be a valuable resource for various professionals and students across medical disciplines, including human genetics and genomics, oncology, neuroscience, gene therapy, molecular medicine, pharmacology, and biomedical sciences. Updates with regard to diagnostic testing, pharmacogenetics, predicting disease susceptibility, and other important research components as well as chapters dedicated to cardiovascular disease, oncology, inflammatory disease, metabolic disease, neuropsychiatric disease, and infectious disease, present this book as an essential tool for a variety of professionals and students who are endeavouring into the developing the diverse and practical field of genomic and personalized medicine.* Full color throughout* Includes contributions on genetic counselling, ethical, legal/regulatory, and social issues related to the practice of genomic medicine from leaders in the field * Introductory chapter ...From:melissawatkins987Views:0 0ratingsTime:00:10More inPeople Blogs

See the original post here:
Essentials Of Genomic And Personalized Medicine - Video

Advocation against Gene Therapy
Antony Vorobyov ENG 111 NK Ms. Soares 11-14-2011From:Antony VorobyovViews:1 0ratingsTime:05:17More inFilm Animation

See more here:
Advocation against Gene Therapy - Video

Clinical Pharmacology: Current Topics And Case Studies
ll4.me Clinical Pharmacology: Current Topics And Case Studies 1. Introduction- The discipline of Clinical Pharmacology- Markus Mller; Professor of Clinical Pharmacology, Vienna, Austria- Example: EACPT position paper- Current issues in drug development- Markus Mller; Professor of Clinical Pharmacology, Vienna, Austria- Example: Pfizer- Current issues in drug regulation- Marcus Mllner / Hans Georg Eichler; Professor and Head, Austrian Medicines Agency AGES, Vienna, Austria / Professor and Senior Medical Officer, EMEA, London, UK- Example: EMEA - Current issues in drug reimbursement- Anna Bucsics; Medical Director, Austrian Board of Social Security Institutions- Example: comparative effectiveness - 2. Clinical Trials- Ethics of clinical research- Ernst Singer; Professor and Head, Ethics Committee, Medical University Vienna, Austria- Example: Nrnberg, Helsinki, Belmont- GCP, Scientific misconduct- Brigitte Blchl-Daum; Professor of Clinical Pharmacology, Vienna, Austria- Example: Tuskegee, Vioxx- Phases of drug development, first in man studies- Bernd Jilma; Professor of Clinical Pharmacology, Vienna, Austria- Example: Tegenero- Clinical trials interventional studies- Michael Wolzt; Professor of Internal Medicine, Vienna, Austria- Example: CAST- Clinical trials observational studies- Ch. Male / H. Herkner; Professor of Pediatrics, Vienna, Austria/ Professor of Internal Medicine, Vienna, Austria- Example: CDC "Outbreak"- Pharmacokinetics / Pharmacodynamics- Hartmut Derendorf ...From:meganhorne326Views:1 0ratingsTime:00:12More inPeople Blogs

Originally posted here:
Clinical Pharmacology: Current Topics And Case Studies - Video

Introduction To Molecular Medicine And Gene Therapy
ll4.me Introduction To Molecular Medicine And Gene Therapy EAN/ISBN : 9780471461043 Publisher(s): John Wiley Sons, Wiley Format: ePub/PDF Author(s): Kresina, Thomas F. EAN/ISBN : 9780471461043 Publisher(s): John Wiley Sons, Wiley Format: ePub/PDF Author(s): Kresina, Thomas F.From:Blancathompson7854Views:0 0ratingsTime:00:15More inPeople Blogs

Read this article:
Introduction To Molecular Medicine And Gene Therapy - Video

Textbook Of Hemophilia
ll4.me Textbook Of Hemophilia The only up-to-date definitive reference source on hemophiliaThis book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders.Textbook of Hemophilia is ideal for:Trainees and residents in hematology Hematologists in practice Specialists working in thrombosis and hemostasis as well as transfusion medicineWhy Buy This Book?The only up-to-date definitive reference source on hemophiliaEssential for all those managing hemophilia patients Detailed guidance on assessment, diagnosis, management and treatment Advice for everyday clinical questions Edited by three of the world #39;s leading experts on hemophilia Publisher: Wiley-Blackwell Illustration: N Language: ENG Title: Textbook of Hemophilia Pages: 00400 (Encrypted PDF) On Sale: 2008-07-15 SKU-13/ISBN: 9781405127691 Category: Medical : Hematology The only up-to-date definitive reference source on hemophiliaThis book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia.From:dorethalopez5478Views:0 0ratingsTime:00:12More inPeople Blogs

Read the rest here:
Textbook Of Hemophilia - Video

New era medicine: Reversal of a family #39;s heart rhythm disorder
In a world first, Sydney researchers have used gene-based therapy to successfully reverse an inherited heart rhythm disorder in members of an entire family, some of whom had previously been told they had only months to live. This gene-therapy, practised as part of the new era of personalised medicine, achieved remarkable results. The research is published in the Journal of the American College of Cardiology. Rather than using conventional heart failure medicine, the researchers from the Victor Chang Cardiac Research Institute in Sydney, identified and treated the gene mutation that caused their heart rhythm disorder, dilated cardiomyopathy (DCM). Many patients with severe disease returned to full health within 6 months. Find out more about this research and the work of the Victor Chang Institute at http://www.victorchang.org.auFrom:VCCRIViews:30 0ratingsTime:02:42More inScience Technology

See the original post:
New era medicine: Reversal of a family's heart rhythm disorder - Video

Hemophilia - Jeri Freedman
ll4.me Hemophilia - Jeri Freedman Cutting-edge scientific breakthroughs in treating hemophilia, including gene therapy and recombinant DNA technology, are described. Symptoms of the disease are also detailed, providing a clear picture of what it is like to live with this ?royal disease.?Author: Freedman, Jeri Publisher: Rosen Young Adult Illustration: N Language: ENG Title: Hemophilia Pages: 00064 (Encrypted PDF) On Sale: 2007-01-01 SKU-13/ISBN: 9781404206984 Category: Juvenile Nonfiction : General Cutting-edge scientific breakthroughs in treating hemophilia, including gene therapy and recombinant DNA technology, are described. Symptoms of the disease are also detailed, providing a clear pictur jeri freedman, juvenile nonfiction, generalFrom:lamarsmith9854Views:0 0ratingsTime:00:11More inPeople Blogs

Go here to see the original:
Hemophilia - Jeri Freedman - Video

Gene Therapy-2012 Opening Ceremony
Gene Therapy-2012 Opening CeremonyFrom:omicsvideosViews:0 0ratingsTime:01:23More inScience Technology

Go here to see the original:
Gene Therapy-2012 Opening Ceremony - Video

cord blood | Cord Blood Cells - Advantages Of Extracting Stem Cells From Umbilical Cord
http://www.cordbloodrecommendation.com The real treatment takes place when the patient is infused with stem cells, which start producing white blood cells in order to make the amount of white blood cells reach the normal number. The nerve cells are known as the ""substantia nigra. Chronic Myelogenous Leukemia Chronic Lymphocytic Leukemia Juvenile Chronic Myelogenous Leukemia Hunter #39;s Syndrome Tay-Sachs Disease Wolman Disease Lesch-Nyhan Syndrome Osteoporosis Beta Thalassemia Major Samples of twin pregnancies were generally rejected due the low availability of cells. The banking facility helps in making blood donation readily available for transplantation #39;s. Flex blood caching can be lifesavers for your family too. She sought umbilical cord blood stem cell therapy from the private Preventative Medicine Clinic in the Netherlands. Stromal cells are a kind of cells that form bone, cartilage, fat, and fibrous connective tissue. Twenty-five children diagnosed with Krabbe #39;s disease were followed and studied regarding their treatments. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Red blood cells, white blood cells and platelets develop from these cells. The phenomenon is growing fast and the situation is unclear. The blood needs to be collected within 10 to fifteen minutes of birth which is why arrangements must be made ahead of time. If they are able to grow sufficiently, the new cell will make new blood ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

Read more from the original source:
cord blood | Cord Blood Cells - Advantages Of Extracting Stem Cells From Umbilical Cord - Video

umbilical cord blood | Cord Blood - Life Saving Out of the Womb
http://www.cordbloodrecommendation.com The collected blood should be processed by specialists in the laboratory within 48 hours and stored properly. Stems cells are very important. Again, these are not hard and fast numbers but just estimates. This procedure also supplies a rapid chromosome analysis within high levels of accuracy. As we all know that it is rich in Hematopoietic stem cells. Extracting bone marrow is a very painful and difficult procedure, and if you have your own blood, then you do not need to make your family members go through the bone marrow transplant procedure. If your child is able to pass the pre-screening process, the program has been highly regarded and is an excellent, free alternative to private registry. Preserved stem cells are used when the body is in a weakened state from disease or treatments such as chemotherapy. Cord blood stem cell therapy has regenerative characteristics. This kind of disease typically attacks the neurons of the central nervous system in the brain. If they decide to donate to a public facility, there are no storage fees however because of privacy concerns all identification features are removed from that particular storage lot within a few years. How many years can a baby #39;s cord blood be saved?Cord blood banking is a relatively new concept. If they are able to grow sufficiently, the new cell will make new blood cells. If you have stem cells of your child, then you will not even need to find bone marrow donors in case your child isFrom:Implantes DentalesViews:0 0ratingsTime:01:18More inScience Technology

Follow this link:
umbilical cord blood | Cord Blood - Life Saving Out of the Womb - Video

cord blood bank | Cheapest Cord Blood Banking
http://www.cordbloodrecommendation.com Cord blood will be the right answer for some diseases. One case is that of Stephen Sprague who was diagnosed with Chronic Myelogenous Leukemia (CML) in 1995. Once you catalog with a cord blood cache, they forward you a kit, containing all the crucial gear for collecting cord blood, along with instructions for the presence doctor, imparter or attention employees. As a parent, we have a choice. It will be easier to take advantage of these new possibilities if you have your own cord blood available for use. She sought umbilical cord blood stem cell therapy from the private Preventative Medicine Clinic in the Netherlands. Another practical application of storing umbilical cord blood after birth is that it can be used for cardiovascular diseases. Everybody, right from the parents to the obstetrician, and the concerning blood bank has to be ready for storage before the baby is born. Why? Because, they say, a public pool to draw on is considerably larger than having a single source of blood. A courier from the stem cell bank will come and retrieve the collection kit and transport for processing and storage. If you can afford to harvest and store your newborns cord blood by all means does so. Although only about 2 cups of cord blood can be collected from the umbilical cord at birth, this small amount is rich in these early (primitive) cells. The closer the blood relation of the cell donor means the more likely that these cells will be helpful. On ...From:luisantafeViews:0 0ratingsTime:01:18More inScience Technology

See the original post:
cord blood bank | Cheapest Cord Blood Banking - Video

blood banks | Facts You May Not Know About Storing Cord Blood
http://www.cordbloodrecommendation.com These findings bring new hope to those who suffer from acute kidney failure, a life threatening condition. One of the studies was carried out by the Wake Forest University which is located in Winston-Salem, N. Lastly, what is their pricing structure like? Trust me, I know that this isn #39;t the time to go bargain hunting, but neither is it the time to be the victim of price-gouging. These trained and knowledgeable individuals will be able to answer any and all questions regarding cord blood storage and the fees and tasks associated with the storage. There is much controversy regarding the use of stem cell research as it pertains to the use of embryos. Extracting bone marrow is a very painful and difficult procedure, and if you have your own blood, then you do not need to make your family members go through the bone marrow transplant procedure. In order to keep it sterilized, it is then cryogenically stored either in a public or private bank until it is needed for transplant. Preserved stem cells are used when the body is in a weakened state from disease or treatments such as chemotherapy. Cord blood stem cell therapy has regenerative characteristics. Stem cell transplants can save lives of people with serious diseases, such as leukemia (cancer of the white blood cells) and other cancers, or those with serious blood disorders (aplastic anemia). There are currently studies which are researching the possibility of using stem cells to treat ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

See the original post:
blood banks | Facts You May Not Know About Storing Cord Blood - Video

stem cell therapy @ kapuso jessica soho
LAMININE It #39;s not often that the perfect super-supplement with the perfect story comes around, but the story of Laminine is far from a mythical tale. As far back as 1929, a Medical Doctor in Canada discovered a way to extract the #39;life-essence #39; of a nine day old fertilized avian egg. Through research, it was found that on exactly the ninth day, all the ingredients necessary to create life are at its #39; highest level. In fact, the life-giving proteins are so potent at this stage that a live chick is hatched a mere two weeks thereafter. This method of extraction and freeze-drying processes proved to be a historical monumental success for this Medical Doctor #39;s patients. 09333737867 for infoFrom:xpalfredViews:5 1ratingsTime:12:00More inHowto Style

Here is the original post:
stem cell therapy @ kapuso jessica soho - Video

Rejuvenare - I don #39;t have time to wait for approval in the US
Patient Jerry relates why he chose Rejuvenare stem cell therapy to treat Parkinson #39;s outside the US. Although he #39;d earlier been successful keeping the disease #39;s progression slowed, they were no longer effective for him and he was told it would be about 10 years before this procedure was approved in the USFrom:rejuvenareViews:0 0ratingsTime:01:24More inEducation

See more here:
Rejuvenare - I don't have time to wait for approval in the US - Video

Stem Cells, FDA, Legal and Regulated elsewhere.mov
Rejuvenare on stem cell therapy, not approved by the FDA in the United States but legal and regulated in other countries.From:rejuvenareViews:0 0ratingsTime:00:23More inEducation

See the original post:
Stem Cells, FDA, Legal and Regulated elsewhere.mov - Video

The Rejuvenare Experience .mov
Patient Jerry and his wife discuss their Rejuvenare experience in Jerry receiving stem cell therapy for Parkinson #39;s disease. They are very impressed with how fantastic the experience has been and wonders how Rejuvenare can offer such excellent services to its patient clients.From:rejuvenareViews:0 0ratingsTime:01:11More inEducation

Link:
The Rejuvenare Experience .mov - Video

Rejuvenare stem cell treatment for stroke.mov
Rejuvenare CEO Carlo Velarde relates how his mother, completely incapacitated by a crippling stroke, has regained her quality of life, her mobility, her thought process after undergoing stem cell therapy for stroke.From:rejuvenareViews:0 0ratingsTime:00:47More inEducation

Continued here:
Rejuvenare stem cell treatment for stroke.mov - Video

VCARE STEM CELL THERAPY
Vcare has launched two treatments options based on stem cell products, one for diffused alopecia, the reversible form of hair loss and one for Androgenetic alopecia, commonly called as "Baldness".From:VCare TrichologyViews:1 0ratingsTime:04:36More inHowto Style

View original post here:
VCARE STEM CELL THERAPY - Video

David Kekich - Stem Cell Therapy Breakthrough
Centagen is developing technology to help millions of people who suffer from chronic pain, disease and injury with an advanced form of adult stem cell therapy. For more information go to http://www.indiegogo.comFrom:CentagenViews:8 0ratingsTime:02:35More inScience Technology

Read the original post:
David Kekich - Stem Cell Therapy Breakthrough - Video

Image-guided cell therapy
In vivo image-guided cell therapy has revolutionised medicine: ENCITE (European Network for Cell Imaging and Tracking Expertise) - a European-wide extensive collaboration on translational research and its impact on healthcare problems that affect our every day lives.From:Eva GruberViews:13 0ratingsTime:08:46More inScience Technology

Link:
Image-guided cell therapy - Video

Muscular contusions are now being treated successfully using cell therapy at The Center for Regenerative medicine in Miami, according to Dr. Farshchian.

(PRWEB) November 15, 2012

Contusions in sports injuries are very common, typically caused by a forceful blow in to the muscle cells, muscle fibers and connective tissue gets damaged, there is some bleeding inside, skin does not break, but usually gets discolored (black and blue) as healing starts. Most contusions are minor and heal quickly without any help by themselves. Healing can be slowed by repeated traumas and not resting the area. Healing can be accelerated by R.I.C.E.

Medication wise dietary supplements known for healing properties such as Zinc and Amino acids may play a role. Low level Lasers may help as well. Sometimes rehabilitating a severe contusion too quickly could cause myositis ossificans in this entity in the bruised area bone may grow instead of muscle cells.

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees, shoulders and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. Their website is http://www.arthritisusa.net

Marty Eugene The Center for Regenerative Medicine 305 8668384 Email Information

More:
Muscular Contusions Are Now Being Treated Successfully Using Cell Therapy

NEW YORK, Nov. 15, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced it ranked number 1 in the Tri-State region and number 7 nationally on Deloitte's 2012 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.

Dr. Robin L. Smith, NeoStem's Chairman and CEO, said "We are proud to be recognized for this achievement as we build NeoStem into a top tier biopharmaceutical company and thrilled to be honored alongside such fast-growing, successful companies such as Celgene, LinkedIn, and Google. On behalf of the entire NeoStem team, I would like to thank Deloitte & Touche, LLP for their recognition of our efforts."

NeoStem is emerging as a market leader in the fast growing cell therapy industry. The Company's multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program providing for near- and long-term revenue growth opportunities. We focus on developing cell therapy products around a strong IP portfolio. These products are focused on large markets such as cardiovascular disease, autoimmune disorders and regenerative medicine.

In a challenging economy with risk adverse capital markets, we have fashioned a management team that is both flexible and opportunistic. PCT, acquired in 2011, expands our revenue growth and gives us unique insight into the clinical and commercial cell therapy manufacturing market while we simultaneously develop our own clinical products. This service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries.

NeoStem is focused on organic growth and continuously evaluates strategic opportunities. We look forward to achieving success for our future patients, our PCT clients, employees and shareholders.

About Deloitte's 2012 Technology Fast 500(TM)

Technology Fast 500, conducted by Deloitte & Touche LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies -- both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2007 to 2011.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

See original here:
NeoStem Ranked Number 1 Fastest Growing Company in the Tri-State Region on Deloitte's 2012 Technology Fast 500(TM)

Princess Margaret Cancer Program will implement ComprehensiveBMT and Investigate Cell Therapy to continue leading role in cancer care and research

SALT LAKE CITY , Nov. 14, 2012 /CNW/ - Remedy Informatics, the leading provider of registries and research informatics software for Life Science and Translational Research and Healthcare, today announced the Princess Margaret Cancer Centre at University Health Network in Toronto has selected ComprehensiveBMT and Investigate Cell Therapy, two of Remedy's innovative clinical informatics solutions.

(Logo: http://photos.prnewswire.com/prnh/20120206/SF47874LOGO)

"The Princess Margaret is one of the largest comprehensive cancer facilities in the world with the largest Blood and Marrow Transplant program in Canada and a gold standard cancer research facility," said Gary Kennedy , Founder and CEO of Remedy Informatics. "Both InvestigateCT and ComprehensiveBMT offer unmatched integration of information to improve treatment outcomes by aggregating, mapping, harmonizing and analyzing data across clinical and scientific disciplines. Valuable information will give valuable insights into patient safety, patient survivorship, and quality improvement for transplant physicians, nurses and researchers."

Built on Remedy's flagship Mosaic Platform, InvestigateCT and ComprehensiveBMT offer the Princess Margaret the world's first and only truly integrated research management system. In addition to combining blood and marrow registries with cell therapy laboratories and biobanks, clinicians and researchers will have an unprecedented view of their data through the Mosaic Ontology, which aggregates, maps and harmonizes the data to facilitate pattern recognition. Together researchers are able to manage and aggregate more data sources, across disciplines, including next-generation sequencing, cross-disease registries, LIMS and the Blood and Marrow Transplant Program to advance research of cell therapies, blood and marrow transplantation, and related diseases.

"The future of patient care and innovative research in blood and marrow transplantation requires rapid data analysis to track and improve patient outcomes. We are confident Remedy Informatics can meet our needs," said Dr. John Kuruvilla , MD, FRCP(C), director, Clinical Program, Blood and Marrow Transplant program at the Princess Margaret . "We foresee better information management as the cornerstone for improving patient outcomes in hematologic malignancies."

The Princess Margaret BMT program has an international reputation as a global leader in clinical and research programs and as a gold standard in transplant technologies like Apheresis collections for peripheral stem cell transplant infusions and Extracorporeal Photopheresis for selected graft-vs-host conditions. Over the next year, Remedy will work with the Princess Margaret BMT program to implement InvestigateCT, the world's first Integrated Research Management System designed for cancer centers involved in clinical research using cell therapies. InvestigateCT will facilitate multi-directional data flow throughout the BMT program, cell therapy labs and biobanks to improve real-time analytics, therapies, patient safety, and quality across the transplant care pathway as well as long-term patient survivorship for patients who are living longer and healthier lives.

Remedy serves a wide range of leading Life Science and Translational Research institutions across the country, including the Huntsman Cancer Institute at the University of Utah, Cleveland Clinic's Bariatric and Metabolic Institute and Heart and Vascular Institute, the American Joint Replacement Registry, Baylor Health Care System, and many more.

For more information about Investigate Cell Therapy or ComprehensiveBMT, or Remedy's leading patient registry technology, please visit our website, http://www.remedyinformatics.com. InvestigateCT is for research use only and is not intended for clinical or cell processing purposes.

About Remedy Informatics, Inc.

Visit link:
The Princess Margaret BMT Program Chooses Remedy Informatics' Blood and Marrow Transplant & Cell Therapy Solutions to ...